In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Outset Medical (OM – Research Report). The company’s shares closed yesterday at $4.13.
According to TipRanks, Kalia is a 4-star analyst with an average return of 6.3% and a 52.03% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Atricure, TransMedics Group, and Butterfly Network.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Outset Medical with a $6.40 average price target, implying a 54.96% upside from current levels. In a report released yesterday, RBC Capital also maintained a Hold rating on the stock with a $5.00 price target.
The company has a one-year high of $24.13 and a one-year low of $1.92. Currently, Outset Medical has an average volume of 1.28M.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Outset Medical (OM) Company Description:
Outset Medical Inc is a medical technology company. The company has developed a machine, Tablo, which reduces the cost and complexity of dialysis.
Read More on OM:
- Outset Medical CTO Exit Amidst Cost-Cutting Restructure
- Outset Medical says FDA grants 510(k) clearance of TabloCart with prefiltration
- Stifel says Outset TabloCart with Prefiltration approval earlier than expected
- FDA posts 510(k) approval of Outset Medical’s TabloCart
- Outset Medical U.S. Renal Care in deal to expand U.S. home dialysis
